Benefits of combining <scp>SGLT2</scp> inhibitors and pioglitazone on risk of <scp>MASH</scp> in type 2 diabetes—A real‐world study
Combining SGLT2i and pioglitazone is a potentially useful strategy to ameliorate 'at-risk' MASH in patients with type 2 diabetes.
Authors
- David Tak Wai Lui (ORCID: https://orcid.org/0000-0002-9813-1126)
- Chi‐Ho Lee (ORCID: https://orcid.org/0000-0002-7569-409X)
- Yu Cho Woo
- Chloe Y. Y. Cheung (ORCID: https://orcid.org/0000-0002-7884-5295)
- Kit Man Chan (ORCID: https://orcid.org/0000-0001-8472-8514)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Jimmy Ho‐Cheung Mak (ORCID: https://orcid.org/0000-0002-3241-3809)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
- Karen S.L. Lam (ORCID: https://orcid.org/0000-0001-5757-541X)
- Wing‐Sun Chow
- Carol Ho‐Yi Fong
Institutions
- Queen Mary Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/dom.16049
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.15